Literature DB >> 11482889

Scrapie removal using Planova virus removal filters.

J Tateishi1, T Kitamoto, S Mohri, S Satoh, T Sato, A Shepherd, M R Macnaughton.   

Abstract

As a possible method for reducing the risk of transmissible spongiform encephalopathy (TSE) infection, Planova virus removal filters were tested for their ability to remove scrapie agent ME7. Albumin solution was spiked with high-titre ME7 and filtered through three different pore sizes of Planova filters. Infectivity of the pre- and post-filtration samples was assayed in log dilutions by intracerebral inoculation into C57B1/6 mice. Filtration of albumin solution in the absence or presence of a detergent (Sarkosyl) with Planova 35N (35+/-2 nm mean pore size) removed the contaminating scrapie agent with reduction factors of 4.93 log10 and 1.61 log10, respectively. Filtration, both in the absence and presence of detergent with Planova 15N (15+/-2 nm mean pore size), and in the presence of detergent with Planova 10N (9+/-2 nm mean pore size), showed high levels of scrapie reduction of >5.87 log10, >4.21 log10, and >3.80 log10, respectively, with no residual infectively detected in any of the filtrate samples. The effectiveness of Planova 35N filtration for the removal of infectivity of this TSE agent is greatly reduced in the presence of a strong detergent, but Planova filters with 15 nm or smaller pore size membranes can remove such infectivity at high reduction rates. Copyright 2001 The International Association for Biologicals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11482889     DOI: 10.1006/biol.2001.0269

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  10 in total

1.  The physical relationship between infectivity and prion protein aggregates is strain-dependent.

Authors:  Philippe Tixador; Laëtitia Herzog; Fabienne Reine; Emilie Jaumain; Jérôme Chapuis; Annick Le Dur; Hubert Laude; Vincent Béringue
Journal:  PLoS Pathog       Date:  2010-04-15       Impact factor: 6.823

Review 2.  Current and emerging management options for hereditary angioedema in the US.

Authors:  Tolly G Epstein; Jonathan A Bernstein
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 3.  Susceptibility of cell substrates to PrPSc infection and safety control measures related to biological and biotherapeutical products.

Authors:  Matthew LeBrun; Hongsheng Huang; Xuguang Li
Journal:  Prion       Date:  2008-01-13       Impact factor: 3.931

Review 4.  A common framework for integrated and continuous biomanufacturing.

Authors:  Jonathan Coffman; Mark Brower; Lisa Connell-Crowley; Sevda Deldari; Suzanne S Farid; Brian Horowski; Ujwal Patil; David Pollard; Maen Qadan; Steven Rose; Eugene Schaefer; Joseph Shultz
Journal:  Biotechnol Bioeng       Date:  2021-03-01       Impact factor: 4.530

5.  Conestat alfa for the treatment of angioedema attacks.

Authors:  Benjamin Davis; Jonathan A Bernstein
Journal:  Ther Clin Risk Manag       Date:  2011-07-01       Impact factor: 2.423

6.  Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.

Authors:  Caroline Goussen; Steve Simoneau; Soline Bérend; Christine Jehan-Kimmel; Anne Bellon; Céline Ducloux; Bruno You; Philippe Paolantonacci; Monique Ollivier; Ludovic Burlot; Sami Chtourou; Benoît Flan
Journal:  BioDrugs       Date:  2017-06       Impact factor: 5.807

Review 7.  Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.

Authors:  Kang Cai; Todd M Gierman; JoAnn Hotta; Christopher J Stenland; Douglas C Lee; Dominique Y Pifat; Steve R Petteway
Journal:  BioDrugs       Date:  2005       Impact factor: 5.807

8.  Detection of prion protein particles in blood plasma of scrapie infected sheep.

Authors:  Oliver Bannach; Eva Birkmann; Elke Reinartz; Karl-Erich Jaeger; Jan P M Langeveld; Robert G Rohwer; Luisa Gregori; Linda A Terry; Dieter Willbold; Detlev Riesner
Journal:  PLoS One       Date:  2012-05-02       Impact factor: 3.240

Review 9.  Modern plasma fractionation.

Authors:  Thierry Burnouf
Journal:  Transfus Med Rev       Date:  2007-04

10.  Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.

Authors:  Christoph Kempf; Martin Stucki; Nicola Boschetti
Journal:  Biologicals       Date:  2006-04-03       Impact factor: 1.856

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.